Rapid reversal of psychotic depression using mifepristone - PubMed

Clinical Trial

Rapid reversal of psychotic depression using mifepristone

J K Belanoff et al. J Clin Psychopharmacol. 2001 Oct.

Abstract

The rationale for treating psychotic major depression with glucocorticoid receptor (GR) antagonists is reviewed. Five patients with psychotic major depression were given 600 mg of mifepristone in a 4-day, double-blind, placebo-controlled crossover study. All the patients completed the protocol and adverse effects were not observed or reported. All of the five patients showed substantial improvements in their Hamilton Rating Scale for Depression scores while they were receiving mifepristone, and four of the five patients showed substantial improvement in their Brief Psychiatric Rating Scale scores. Little, if any, improvement was seen with placebo. These preliminary results suggest that short-term use of GR antagonists may be effective in the treatment of psychotic major depression and that additional study, perhaps using higher doses or more treatment days, seems warranted.

Similar articles

• Clinical and biological effects of mifepristone treatment for psychotic depression.

  Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Flores BH, et al. Neuropsychopharmacology. 2006 Mar;31(3):628-36. doi: 10.1038/sj.npp.1300884. Neuropsychopharmacology. 2006. PMID: 16160710 Clinical Trial.

• Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression.

  Block T, Petrides G, Kushner H, Kalin N, Belanoff J, Schatzberg A. Block T, et al. J Clin Psychopharmacol. 2017 Oct;37(5):505-511. doi: 10.1097/JCP.0000000000000744. J Clin Psychopharmacol. 2017. PMID: 28708736 Free PMC article. Clinical Trial.

• Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression.

  DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G. DeBattista C, et al. Biol Psychiatry. 2006 Dec 15;60(12):1343-9. doi: 10.1016/j.biopsych.2006.05.034. Epub 2006 Aug 4. Biol Psychiatry. 2006. PMID: 16889757 Clinical Trial.

• Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression.

  Nihalani ND, Schwartz TL. Nihalani ND, et al. Curr Opin Investig Drugs. 2007 Jul;8(7):563-9. Curr Opin Investig Drugs. 2007. PMID: 17659476 Review.

• Mifepristone as a therapeutic agent in psychiatry.

  Howland RH. Howland RH. J Psychosoc Nurs Ment Health Serv. 2013 Jun;51(6):11-4. doi: 10.3928/02793695-20130513-01. J Psychosoc Nurs Ment Health Serv. 2013. PMID: 23814820 Review.

Cited by

• Corticosteroids, immune suppression, and psychosis.

  Perantie DC, Brown ES. Perantie DC, et al. Curr Psychiatry Rep. 2002 Jun;4(3):171-6. doi: 10.1007/s11920-002-0023-8. Curr Psychiatry Rep. 2002. PMID: 12003678 Review.

• Opposite effects of early maternal deprivation on neurogenesis in male versus female rats.

  Oomen CA, Girardi CE, Cahyadi R, Verbeek EC, Krugers H, Joëls M, Lucassen PJ. Oomen CA, et al. PLoS One. 2009;4(1):e3675. doi: 10.1371/journal.pone.0003675. Epub 2009 Jan 30. PLoS One. 2009. PMID: 19180242 Free PMC article.

• Dynamics of ACTH and Cortisol Secretion and Implications for Disease.

  Lightman SL, Birnie MT, Conway-Campbell BL. Lightman SL, et al. Endocr Rev. 2020 Jun 1;41(3):bnaa002. doi: 10.1210/endrev/bnaa002. Endocr Rev. 2020. PMID: 32060528 Free PMC article. Review.

• Blocking mineralocorticoid receptors impairs, blocking glucocorticoid receptors enhances memory retrieval in humans.

  Rimmele U, Besedovsky L, Lange T, Born J. Rimmele U, et al. Neuropsychopharmacology. 2013 Apr;38(5):884-94. doi: 10.1038/npp.2012.254. Epub 2012 Dec 6. Neuropsychopharmacology. 2013. PMID: 23303058 Free PMC article. Clinical Trial.

• Psychotic major depression: a benefit-risk assessment of treatment options.

  Tyrka AR, Price LH, Mello MF, Mello AF, Carpenter LL. Tyrka AR, et al. Drug Saf. 2006;29(6):491-508. doi: 10.2165/00002018-200629060-00003. Drug Saf. 2006. PMID: 16752932 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wolters Kluwer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information